(Q35050146)

English

An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

14 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

5 September 2019

9 September 2019

2 October 2019

10 October 2019

7 November 2019

8 November 2019

11 November 2019

28 January 2021

28 November 2023

An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

diabetic retinopathy

12 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

5 September 2019

9 September 2019

2 October 2019

10 October 2019

7 November 2019

8 November 2019

11 November 2019

1 reference

5 September 2019

1 reference

9 September 2019

mechanism of action

1 reference

2 October 2019

circulatory system

1 reference

10 October 2019

carboxylic acid

1 reference

7 November 2019

1 reference

8 November 2019

1 reference

7 November 2019

1 reference

11 November 2019

1 reference

28 January 2021

object named as

Alicia J Jenkins

2

0 references

Ecosse L Lamoureux

6

object named as

Ecosse L Lamoureux

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Jonathan E Noonan

1

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jian-Xing Ma

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Anthony C Keech

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Jie Jin Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

language of work or name

0 references

publication date

1 December 2013

15 references

Europe PubMed Central

PubMed publication ID

6 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

5 September 2019

9 September 2019

2 October 2019

10 October 2019

7 November 2019

8 November 2019

11 November 2019

28 January 2021

28 November 2023

15 references

Europe PubMed Central

PubMed publication ID

6 August 2017

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

5 September 2019

9 September 2019

2 October 2019

10 October 2019

7 November 2019

8 November 2019

11 November 2019

28 January 2021

28 November 2023

62

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3968-3975

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

copyright license

Creative Commons Attribution-NonCommercial-NoDerivatives

14 references

13 March 2019

14 March 2019

24 March 2019

25 April 2019

17 June 2019

5 September 2019

9 September 2019

2 October 2019

10 October 2019

7 November 2019

8 November 2019

11 November 2019

28 January 2021

28 November 2023

on focus list of Wikimedia project

0 references

Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Activation of AMP-activated protein kinase prevents lipotoxicity in retinal pericytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Effects of medical therapies on retinopathy progression in type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Apolipoprotein A1 is overexpressed in the retina of diabetic patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Double-blind trial of Atromid-S in exudative diabetic retinopathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Exudative diabetic retinopathy. The use of clofibrate in the treatment of hard exudates using a reduced but prolonged dosage over several years (author's transl)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

8 July 2018

Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Intraretinal leakage and oxidation of LDL in diabetic retinopathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Activation of PPARalpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3837039

25 October 2018

Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxidised, glycated LDL selectively influences tissue inhibitor of metalloproteinase-3 gene expression and protein production in human retinal capillary pericytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A three-year trial of atromid therapy in exudative diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clofibrate PPARα activation reduces oxidative stress and improves ultrastructure and ventricular hemodynamics in no-flow myocardial ischemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent]

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24264394

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2337/DB13-0800

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35050146&oldid=2019545428"